In addition, the expression levels of FBLN5 in cancers such as STES, BLCA, and LUSC could provide guidance regarding whether patients should undergo immunotherapy or targeted therapy, the provision of personalized treatment plans to patients, and improvements in the patient survival rate and quality of life. Here, FBLN5 is linked to cancer.